Aerotek Scientific Acquires Scientific Division of KForce
Aerotek’s clients gain increased access to qualified candidates for their positions with the company's acquisition of Kforce’ scientific division.
Aerotek Scientific® LLC, a subsidiary of Aerotek, Inc., is excited to announce the acquisition of the scientific division of Kforce. Aerotek (
Aerotek acquired the employees, clients, contractors, and relevant data of the scientific division of Kforce. Staff previously employed by the scientific division of Kforce will continue to service their clients and contractors while working for Aerotek Scientific.
Aerotek Scientific places candidates of all levels at a variety of companies in many industries including: pharmaceuticals, biotechnology, healthcare, food & beverage, clinical research, chemical and plastics. The scientific division of Kforce’s similar focus on these markets complements Aerotek’s existing structure and will expand the company throughout the scientific industry. Kforce will retain the recruitment services that apply to the clinical trials industry.
“The acquisition of the scientific division of Kforce strengthens the presence of Aerotek Scientific within niche scientific industries nationwide,” said Thomas M. Thornton, president and chief executive officer of Aerotek. In addition to the internal growth from which our company will benefit, former Kforce Scientific and existing Aerotek clients now have access to a larger pool of qualified candidates for their positions, and contract employees have significantly more jobs available to them through our services.”
As technologies evolve and new career specialties emerge, the market for scientific professionals has continued to increase. The demand for qualified, experienced talent in scientific industries has become progressively competitive. The acquisition of the scientific division of Kforce bolsters Aerotek’s collective expertise and reinforces the company’s position as a leader in this marketplace.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025